
|Articles|March 17, 2004
Inconclusive findings lead Pfizer to stop testing sildenafil in women
Pfizer Inc. has ended its research into sildenafil citrate (Viagra) as a treatment for female sexual arousal disorder (FSAD) after several large studies showed inconclusive efficacy.
Advertisement
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer
3
Individualizing androgen pathway therapy in mCSPC
4
BOND-003 Cohort C: Efficacy Results
5







